DOCTORS'
Medical Case Studies
DOCTORS'
Medical Case Studies
Lucentis
Ranibizumab
Ranibizumab (trade name Lucentis) is a monoclonal antibody fragment derived from the same parent mouse antibody as bevacizumab (Avastin). It is much smaller than the parent molecule and has been affinity matured to provide stronger binding to VEGF-A. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (ARMD), a common form of age-related vision loss. Some investigators believe that bevacizumab at an average cost of $42 a dose (in the U.S. ) is as effective as ranibizumab at an average cost of $1,593 a dose...
Lucentis - List of case studies
- Age Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
-
in the left eye. A treatment option would be additional Lucentis or Avastin intravitreal injections, and the patient should consider ... is still present a treatment option would be additional Lucentis or Avastin intravitreal injections . Most probably this treatment ...
- Myopic Maculopathy
-
to date, however, he is a good candidate for Lucentis or Avastin intravitreal injections into the right eye in ... Medicines : Visudyne , Lucentis, Avastin intravitreal injections. Treatments : ...
- Drugs
-
heparins Low-molecular-weight-heparin Lucen Lucentis Luteal support Lyrica Lyrica (75 mg) M ...
- Degenerative Maculopathy
-
degeneration, which can be treated with injections of Lucentis or Avastin. questions: ... we have today good treatment options with injections of Lucentis or Avastin if she were to develop the wet type of age related ...